Cwm LLC Sells 119 Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO)

Cwm LLC decreased its holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO) by 17.6% in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 556 shares of the medical research company’s stock after selling 119 shares during the period. Cwm LLC’s holdings in Bio-Rad Laboratories were worth $180,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in BIO. Simplicity Solutions LLC boosted its position in Bio-Rad Laboratories by 26.8% during the third quarter. Simplicity Solutions LLC now owns 676 shares of the medical research company’s stock valued at $242,000 after buying an additional 143 shares during the period. Fjarde AP Fonden Fourth Swedish National Pension Fund boosted its holdings in Bio-Rad Laboratories by 412.5% during the 3rd quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund now owns 4,100 shares of the medical research company’s stock valued at $1,470,000 after acquiring an additional 3,300 shares during the period. Xponance Inc. grew its position in Bio-Rad Laboratories by 4.3% during the 3rd quarter. Xponance Inc. now owns 3,296 shares of the medical research company’s stock worth $1,181,000 after acquiring an additional 135 shares during the last quarter. Raymond James & Associates grew its position in Bio-Rad Laboratories by 2.3% during the 3rd quarter. Raymond James & Associates now owns 34,732 shares of the medical research company’s stock worth $12,450,000 after acquiring an additional 767 shares during the last quarter. Finally, New York State Teachers Retirement System increased its stake in Bio-Rad Laboratories by 0.5% in the 3rd quarter. New York State Teachers Retirement System now owns 15,952 shares of the medical research company’s stock worth $5,718,000 after purchasing an additional 84 shares during the period. Institutional investors own 65.24% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on BIO. UBS Group raised their target price on shares of Bio-Rad Laboratories from $395.00 to $420.00 and gave the stock a “buy” rating in a report on Friday, February 16th. Citigroup cut Bio-Rad Laboratories from a “buy” rating to a “neutral” rating and reduced their target price for the company from $400.00 to $365.00 in a research note on Wednesday, April 3rd. Royal Bank of Canada dropped their price target on Bio-Rad Laboratories from $484.00 to $480.00 and set an “outperform” rating for the company in a research note on Friday, February 16th. Finally, StockNews.com raised shares of Bio-Rad Laboratories from a “hold” rating to a “buy” rating in a research report on Thursday, April 25th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $468.00.

Insider Activity

In related news, EVP Michael Crowley sold 3,000 shares of the company’s stock in a transaction dated Tuesday, February 27th. The shares were sold at an average price of $336.00, for a total value of $1,008,000.00. Following the transaction, the executive vice president now owns 6,942 shares in the company, valued at approximately $2,332,512. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 17.06% of the company’s stock.

Bio-Rad Laboratories Price Performance

Shares of BIO stock opened at $279.83 on Friday. Bio-Rad Laboratories, Inc. has a twelve month low of $261.59 and a twelve month high of $468.45. The stock has a market cap of $7.98 billion, a price-to-earnings ratio of -13.02 and a beta of 0.94. The business’s fifty day moving average is $318.52 and its 200 day moving average is $314.90. The company has a quick ratio of 4.34, a current ratio of 5.83 and a debt-to-equity ratio of 0.14.

Bio-Rad Laboratories (NYSE:BIO) last posted its quarterly earnings results on Thursday, February 15th. The medical research company reported $3.10 earnings per share for the quarter, topping the consensus estimate of $2.93 by $0.17. The company had revenue of $681.18 million for the quarter, compared to the consensus estimate of $685.00 million. Bio-Rad Laboratories had a positive return on equity of 3.90% and a negative net margin of 23.86%. The firm’s quarterly revenue was down 6.7% compared to the same quarter last year. During the same quarter in the prior year, the business posted $3.31 EPS. Research analysts expect that Bio-Rad Laboratories, Inc. will post 10.41 EPS for the current fiscal year.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.